Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
1999-04-16
2001-05-15
Kemmerer, Elizabeth C. (Department: 1646)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C514S012200
Reexamination Certificate
active
06232289
ABSTRACT:
SPONSORSHIP
The development of the present invention was supported by the University of Maryland, Baltimore, Md., the Fishbein Foundation, and the Interstitial Cystitis Association.
FIELD OF THE INVENTION
The field of this invention generally relates to the treatment of diseases characterized by bladder epithelial abnormalities using heparin-binding epidermal growth factor-like growth factor (HB-EGF) or a functional derivative thereof to stimulate epithelial cell proliferation. The field of this invention specifically relates to the treatment of Interstitial Cystitis (IC) using recombinant HB-EGF to overcome the inhibition of bladder epithehial cell proliferation caused by a low molecular weight anti-proliferative factor found in the urine of IC patients.
BACKGROUND OF THE INVENTION
Interstitial cystitis (IC) is a chronic inflammatory disease of the bladder for which the etiology is unknown. IC often has a rapid onset with pain, urgency and frequency of urination, and cystoscopic abnormalities including petechial hemorrhages (glomerulations) or ulcers that extend into the lamina propria (Hunner's ulcers)
1,2
. The rapid onset of IC is followed by a chronic course with partial remissions and re-exacerbations, which can continue for up to 30 years
1,2
. As a result of the absence of a specific cause for and lack of understanding of its pathogenesis, there is currently no generally accepted treatment proven to be reliably efficacious.
Various groups have studied IC and speculated as to its cause. Proposed etiologies include infection, allergic or immune disorders, endocrinologic disturbance, toxic urinary chemicals, defective transitional mucosa, psychiatric disorders, neurogenic disorders, lymphatic obstruction, vascular obstruction. Proposed treatments include pentosan polysulfate, anti-inflammatory or immunosuppressant therapy, muscle relaxants, anti-histamines, and analgesics. Of these, only pentosan polysulfate has been approved by the FDA. However, none of the proposed therapies, including pentosan polysulfate, is universally accepted or universally efficacious. As a result, there is a long felt need for adequate therapy of this misunderstood and frequently misdiagnosed disorder.
Certain morphologic and histologic features of IC suggest that the epithelium is usually abnormal in this disease
3-5
, with evidence for changes in the bladder mucin layer
6
, denudation or thinning of the bladder epithelium and rupture of the mucosa
3-5,7
, and intraurothelial infiltration of urinary proteins such as Tamm-Horsfall protein
8
. In addition, activation of bladder epithelial cells appears to be abnormal in IC, with altered expression of specific cellular proteins
9
. These changes coupled with the chronic nature of IC suggests the possibility of impaired regeneration of normal bladder epithelium. In previous experiments, we discovered a 1-3 kDa peptide in the urine of IC patients that inhibits the proliferation of cultured normal adult human bladder epithelial cells, suggesting that it may be related to the pathogenesis of this disorder (see co-pending application Ser. No. 08/944,202). This peptide is hereafter referred to as the anti-proliferative factor or APF.
The uninjured postnatal urothelium regenerates very slowly, but rapid proliferation of uroepithelial cells in vivo can occur during tissue regeneration in response to injury
10
. The limited data that exist for bladder epithelial cells suggest their replication and differentiation are probably influenced by specific paracrine or autocrine growth factors and their regulatory proteins, similar to other types of epithelial cells
10-21
. Epithelial cell growth factors known to be present in normal human urine include epidermal growth factor (EGF), insulin-like growth factors (IGF's), insulin-like growth factor binding proteins (IGFBP's), heparin-binding epidermal growth factor-like growth factor (HB-EGF), platelet-derived growth factors (PDGF-A and B), fibroblast growth factors (FGF1 and 2), and transforming growth factor beta (TGF&bgr;). EGF, which is produced primarily by cells in the thick ascending limb of Henle and the distal convoluted tubule
22
, is present in high concentrations in urine, and can stimulate, but is not required for, mouse bladder epithelial cell proliferation in vitro
23
. IGF1 and IGF2 are produced by both kidney and bladder cells and appear to be required for bladder epithelial cell proliferation
10,21,24
. The major IGFBP's found in human urine, which can regulate the activity of IGF1 and 2, are IGFBP-2 and IGFBP-3
25
. HB-EGF is also known to be produced by human bladder epithelial cells and can stimulate their growth in vitro
26,27
. In contrast, current data suggest that the PDGF's, FGF's and TGF&bgr; affect bladder epithelial cell migration and/or differentiation, but their role in cell proliferation remains uncertain
10,21
.
Exogenously applied growth factors can stimulate epithelial wound repair
11-13
. Since IC is histologically characterized by epithelial abnormalities and because the mucosal defects present in IC result in exposure of basal undifferentiated cells and their growth factor receptors to urine growth factors, we reasoned that abnormally low levels of urinary growth factors, such as HB-EGF, that stimulate bladder epithelial cell proliferation could adversely affect bladder epithelial wound repair and be part of the etiology of IC.
We measured urinary levels of HB-EGF in women with IC, asymptomatic control women without bladder disease, and women with acute, self-limited bladder epithelial damage from bacterial cystitis. We discovered that urine levels of HB-EGF are specifically and significantly decreased in the urine of IC patients (see co-pending application Ser. No. 60/051,458). Furthermore, recent data indicate that 1) IC urine contains a low molecular weight anti-proliferative factor (APF) that specifically inhibits HB-EGF production by primary human bladder epithelial cells in vitro and 2) the inhibition of bladder epithelial cell proliferation caused by the APF from IC urine specimens can be blocked by the addition of recombinant HB-EGF to the cell medium.
Based on the above, we have concluded that 1) a low molecular weight factor from IC urine (APF) inhibits HB-EGF production by bladder epithelial cells and 2) HB-EGF may be used as a therapeutic to stimulate bladder epithelial cell proliferation in the presence of the APF, thereby effectively treating IC.
SUMMARY OF THE INVENTION
It is the object of the invention to provide a reliably effective therapy for diseases associated with inhibited epithelial cell proliferation, particularly bladder epithelial cell proliferation, more particularly interstitial cystitis (IC), using heparin-binding epidermal growth factor-like growth factor (HB-EGF) which is capable of inhibiting the anti-proliferative activity present in most IC urine specimens or an analogue, variant, or derivative thereof having the same functional activity and capability.
It is a further object of the invention to administer HB-EGF or agents that stimulate HB-EGF production or mimic its activity to injured epithelial cells in a form suitable to provide the desired inhibition of anti-proliferation or stimulation of cell replication. The form may be suitable for exogenous or endogenous application. The form may be suitable for local or topical application, such as a liquid, a cream, an ointment, a suppository, or a gel that may be superficially applied to the tissues. Alternatively, the form may be suitable for systemic administration, such as oral or parenteral formulations. The administration may be in the form of discrete doses or in a form capable of continuous delivery.
It is a further object of the invention to administer an agonist of HB-EGF or agents that increase the efficacy of HB-EGF in a subject. As described in detail herein, an agonist of HB-EGF is any compound which is capable of increasing the efficacy of a function of HB-EGF and includes, for example, agents which promote the synthesis of HB-EGF by the subject, etc.
It
Hise Michael
Keay Susan
Warren John
Barrett William A.
Hultquist Steven J.
Kemmerer Elizabeth C.
University of Maryland Baltimore
LandOfFree
Method of treating interstitial cytitis with recombinant... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method of treating interstitial cytitis with recombinant..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method of treating interstitial cytitis with recombinant... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2436867